Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer

Authors

  • Angelos K. Koutras Division of Oncology, Department of Medicine, University Hospital of Patras, Patras Medical School, Rio, 26504, Greece
  • Nicholas S. Mastronikolis Department of Otorhinolaryngology, University Hospital of Patras, Patras Medical School, Rio, 26504, Greece
  • Tr Jeffry Evans Cancer Research UK Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK
  • Evangelos S. Papadeas Department of Otorhinolaryngology, University Hospital of Patras, Patras Medical School, Rio, 26504, Greece
  • Thomas Makatsoris Division of Oncology, Department of Medicine, University Hospital of Patras, Patras Medical School, Rio, 26504, Greece
  • Haralabos P. Kalofonos Division of Oncology, Department of Medicine, University Hospital of Patras, Patras Medical School, Rio, 26504, Greece

DOI:

https://doi.org/10.1080/02841860802213328

Abstract

No Abstract Available

Downloads

Download data is not yet available.

Downloads

Published

2008-01-01

How to Cite

Koutras, A. K. ., Mastronikolis, N. S. ., Jeffry Evans, T. ., Papadeas, E. S. ., Makatsoris, T. ., & Kalofonos, H. P. . (2008). Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncologica, 47(6), 1171–1173. https://doi.org/10.1080/02841860802213328

Issue

Vol. 47 No. 6 (2008): Acta Oncologica

Section

Articles